Why Eli Lilly and Palo Alto Networks are both up on news from their competitors

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

GE Healthcare shows signs of life, but a lingering uncertainty keeps us on the sidelines

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

Jim Cramer looks at reasons for the market decline and provides new views on 3 stocks

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

Lost in the market’s sharp rotation out of tech stocks is a really bullish call on major banks

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

We’re encouraged by Abbott stock trading but discouraged by moves in Honeywell

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

FDA approval of Eli Lilly’s Alzheimer’s drug cements our decision not to take profits

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

We’re encouraged by an activist’s willingness to buy an Abbott rival, look past baby formula suits

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…